Australia markets open in 5 hours 51 minutes

Castle Biosciences, Inc. (CSTL)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
27.78-1.38 (-4.73%)
As of 01:07PM EDT. Market open.
Currency in USD

Valuation measures4

Market cap (intra-day) 788.91M
Enterprise value 523.43M
Trailing P/E 478.00
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)6.94
Price/book (mrq)1.87
Enterprise value/revenue 4.75
Enterprise value/EBITDA -10.97

Trading information

Stock price history

Beta (5Y monthly) 1.14
52-week change 3-55.18%
S&P500 52-week change 3-14.01%
52-week high 368.65
52-week low 315.58
50-day moving average 329.03
200-day moving average 331.32

Share statistics

Avg vol (3-month) 3208.67k
Avg vol (10-day) 3182.46k
Shares outstanding 526.3M
Implied shares outstanding 6N/A
Float 824.89M
% held by insiders 14.85%
% held by institutions 186.39%
Shares short (14 Sept 2022) 41.16M
Short ratio (14 Sept 2022) 47.26
Short % of float (14 Sept 2022) 45.29%
Short % of shares outstanding (14 Sept 2022) 44.41%
Shares short (prior month 14 Aug 2022) 41.2M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2021
Most-recent quarter (mrq)29 June 2022


Profit margin -40.37%
Operating margin (ttm)-66.52%

Management effectiveness

Return on assets (ttm)-10.25%
Return on equity (ttm)-10.62%

Income statement

Revenue (ttm)110.2M
Revenue per share (ttm)4.32
Quarterly revenue growth (yoy)53.10%
Gross profit (ttm)78.26M
EBITDA -67.95M
Net income avi to common (ttm)-44.49M
Diluted EPS (ttm)-2.04
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)273.17M
Total cash per share (mrq)10.39
Total debt (mrq)7.85M
Total debt/equity (mrq)1.86
Current ratio (mrq)11.08
Book value per share (mrq)16.04

Cash flow statement

Operating cash flow (ttm)-39.34M
Levered free cash flow (ttm)-13.61M